Market maturation of a blood plasma separation module enabling plasma based diagnostic point-of-care devices

Información del proyecto

ACOUPLASMA

Identificador del acuerdo de subvención: 836542

DOI

10.3030/836542

Proyecto cerrado

Fecha de la firma de la CE 26 Noviembre 2018

Fecha de inicio 1 Octubre 2018

Fecha de finalización 28 Febrero 2019

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

ACOUSORT AB
Sweden

Periodic Reporting for period 1 - ACOUPLASMA (Market maturation of a blood plasma separation module enabling plasma based diagnostic point-of-care devices)

Período documentado: 2018-10-01 hasta 2019-02-28

Resumen del contexto y de los objetivos generales del proyecto

Given the rapid ageing of the population and rise in chronic diseases, it is now more critical than ever to develop new solutions that positively impact the global healthcare system and the population wellbeing.
AcouSort has developed a technological platform based on acoustic forces to separate, enrich and wash cells and other particles This technique can perform almost any operation that is normally done by centrifugation in the biology or clinical lab. With an automated flow we can handle small samples and low cell concentrations. We are currently selling two R&D benchtop devices based on this technology, named AcouTrap and AcouWash.
In our pipeline is AcouPlasma the first example of the company’s long-term strategy to provide components and modules for life science analytical/diagnostic devices. The AcouPlasma solution offers high quality separation of blood plasma from cells in whole blood in a module, eliminating the need of time consuming and laborious centrifugation. Through a unique design, it facilitates cost-effective automation and in-line integration with the sample workflow required to take plasma-based laboratory tests to point-of-care.
It is now time to mature our solution towards a commercial device to be integrated into cartridges for Lab-on-Chip test devices for the in vitro diagnostic market. The Phase 1 project was aimed at developing an in-depth business plan.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

In line with the main objective of the SME instrument Phase 1 project, we have during the action:
1) Started to map and engage with key stakeholders, including suppliers and customers
2) Developed an in-depth market study compiling it into a business plan
3) Performed a Freedom to operate analysis
4) Prepared the Phase 2 project.
Most importantly, we have during the project confirmed that our solution clearly addresses the issues described above, matching customers and end-users’ needs.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

There is currently a lack of cost-effective Lab-on-a-chip solutions for blood plasma separation for integration into plasma-based diagnostic devices, which is limiting the point-of-care market expansion. AcouPlasma´s performance has potential to increase patient safety and hospitals/laboratories efficiency, finances and reputation.

acouplasma.jpg